Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis

Jeong Won Jang, Jong Young Choi, Young Seok Kim, Jeong Ju Yoo, Hyun Young Woo, Sung Kyu Choi, Chung Hwan Jun, Chang Hyeong Lee, Joo Hyun Sohn, Won Young Tak, Yu Rim Lee, KwangHyub Han

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background & Aims: Little is known about the effects of antiviral therapy on short- and long-term survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis. We aimed to determine whether a maintained virologic response (MVR, defined as persistent undetectable HBV DNA during therapy) associates with short-term (6 mo) and long-term (6–120 mo) survival of patients with decompensated cirrhosis. Methods: We performed a 10-year observation analysis using data from the Epidemiology and Natural History of Liver Cirrhosis study of patients with decompensated liver cirrhosis in Korea. Of the entire cohort (1595 patients enrolled at onset of decompensation since 2005), our analysis comprised 295 patients who immediately began treatment with entecavir (n = 179) or lamivudine (n = 116) after decompensation. We collected laboratory test results, data on hepatocellular carcinoma (HCC) development, and Child–Turcotte–Pugh and model for end-stage liver disease (MELD) scores. The mean follow-up time was 62.3 ± 36.5 months. The primary end point was time of liver transplant-free survival. Results: The median survival time was 7.7 years; 60.1% of patients survived for 5 years and 45.7% survived for 10 years without liver transplantation. An MVR was observed in 116 patients (39.3%); these patients had significantly longer times of transplant-free survival than patients without MVR. Survival times associated with the occurrence of HCC; survival of patients without HCC was excellent if they survived the first 6 months after initiation of antiviral therapy, whereas the survival rates of patients with HCC decreased persistently over time. A baseline MELD score above 20 and multiple complications were associated with short-term mortality. MVR was the factor most strongly associated with long-term transplant-free survival. Significantly higher proportions of patients who received entecavir survived 10 years compared with patients who received lamivudine, but no difference was observed among patients with MVRs. Patients with MVRs had significant improvement in hepatic function over time, but nonsignificant reductions in risk of HCC or HCC-related mortality. Conclusions: In a 10-year observation study of patients in Korea with HBV-related decompensated cirrhosis, we found baseline MELD score and MVR to entecavir or lamivudine to associate with short- and long-term transplant-free survival. The benefits of an MVR are maintained for up to 10 years even after decompensation, but patients are still at risk for HCC.

Original languageEnglish
Pages (from-to)1954-1963.e3
JournalClinical Gastroenterology and Hepatology
Volume16
Issue number12
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Fibrosis
Hepatocellular Carcinoma
Survival
Therapeutics
End Stage Liver Disease
Lamivudine
Transplants
Korea
Liver Cirrhosis
Antiviral Agents
Observation
Mortality
Liver
Risk Reduction Behavior
Genetic Therapy
Liver Transplantation

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Jang, Jeong Won ; Choi, Jong Young ; Kim, Young Seok ; Yoo, Jeong Ju ; Woo, Hyun Young ; Choi, Sung Kyu ; Jun, Chung Hwan ; Lee, Chang Hyeong ; Sohn, Joo Hyun ; Tak, Won Young ; Lee, Yu Rim ; Han, KwangHyub. / Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. In: Clinical Gastroenterology and Hepatology. 2018 ; Vol. 16, No. 12. pp. 1954-1963.e3.
@article{f1f33336a52f41a0a7594ec10f02c68f,
title = "Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis",
abstract = "Background & Aims: Little is known about the effects of antiviral therapy on short- and long-term survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis. We aimed to determine whether a maintained virologic response (MVR, defined as persistent undetectable HBV DNA during therapy) associates with short-term (6 mo) and long-term (6–120 mo) survival of patients with decompensated cirrhosis. Methods: We performed a 10-year observation analysis using data from the Epidemiology and Natural History of Liver Cirrhosis study of patients with decompensated liver cirrhosis in Korea. Of the entire cohort (1595 patients enrolled at onset of decompensation since 2005), our analysis comprised 295 patients who immediately began treatment with entecavir (n = 179) or lamivudine (n = 116) after decompensation. We collected laboratory test results, data on hepatocellular carcinoma (HCC) development, and Child–Turcotte–Pugh and model for end-stage liver disease (MELD) scores. The mean follow-up time was 62.3 ± 36.5 months. The primary end point was time of liver transplant-free survival. Results: The median survival time was 7.7 years; 60.1{\%} of patients survived for 5 years and 45.7{\%} survived for 10 years without liver transplantation. An MVR was observed in 116 patients (39.3{\%}); these patients had significantly longer times of transplant-free survival than patients without MVR. Survival times associated with the occurrence of HCC; survival of patients without HCC was excellent if they survived the first 6 months after initiation of antiviral therapy, whereas the survival rates of patients with HCC decreased persistently over time. A baseline MELD score above 20 and multiple complications were associated with short-term mortality. MVR was the factor most strongly associated with long-term transplant-free survival. Significantly higher proportions of patients who received entecavir survived 10 years compared with patients who received lamivudine, but no difference was observed among patients with MVRs. Patients with MVRs had significant improvement in hepatic function over time, but nonsignificant reductions in risk of HCC or HCC-related mortality. Conclusions: In a 10-year observation study of patients in Korea with HBV-related decompensated cirrhosis, we found baseline MELD score and MVR to entecavir or lamivudine to associate with short- and long-term transplant-free survival. The benefits of an MVR are maintained for up to 10 years even after decompensation, but patients are still at risk for HCC.",
author = "Jang, {Jeong Won} and Choi, {Jong Young} and Kim, {Young Seok} and Yoo, {Jeong Ju} and Woo, {Hyun Young} and Choi, {Sung Kyu} and Jun, {Chung Hwan} and Lee, {Chang Hyeong} and Sohn, {Joo Hyun} and Tak, {Won Young} and Lee, {Yu Rim} and KwangHyub Han",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.cgh.2018.04.063",
language = "English",
volume = "16",
pages = "1954--1963.e3",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "12",

}

Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. / Jang, Jeong Won; Choi, Jong Young; Kim, Young Seok; Yoo, Jeong Ju; Woo, Hyun Young; Choi, Sung Kyu; Jun, Chung Hwan; Lee, Chang Hyeong; Sohn, Joo Hyun; Tak, Won Young; Lee, Yu Rim; Han, KwangHyub.

In: Clinical Gastroenterology and Hepatology, Vol. 16, No. 12, 01.12.2018, p. 1954-1963.e3.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis

AU - Jang, Jeong Won

AU - Choi, Jong Young

AU - Kim, Young Seok

AU - Yoo, Jeong Ju

AU - Woo, Hyun Young

AU - Choi, Sung Kyu

AU - Jun, Chung Hwan

AU - Lee, Chang Hyeong

AU - Sohn, Joo Hyun

AU - Tak, Won Young

AU - Lee, Yu Rim

AU - Han, KwangHyub

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background & Aims: Little is known about the effects of antiviral therapy on short- and long-term survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis. We aimed to determine whether a maintained virologic response (MVR, defined as persistent undetectable HBV DNA during therapy) associates with short-term (6 mo) and long-term (6–120 mo) survival of patients with decompensated cirrhosis. Methods: We performed a 10-year observation analysis using data from the Epidemiology and Natural History of Liver Cirrhosis study of patients with decompensated liver cirrhosis in Korea. Of the entire cohort (1595 patients enrolled at onset of decompensation since 2005), our analysis comprised 295 patients who immediately began treatment with entecavir (n = 179) or lamivudine (n = 116) after decompensation. We collected laboratory test results, data on hepatocellular carcinoma (HCC) development, and Child–Turcotte–Pugh and model for end-stage liver disease (MELD) scores. The mean follow-up time was 62.3 ± 36.5 months. The primary end point was time of liver transplant-free survival. Results: The median survival time was 7.7 years; 60.1% of patients survived for 5 years and 45.7% survived for 10 years without liver transplantation. An MVR was observed in 116 patients (39.3%); these patients had significantly longer times of transplant-free survival than patients without MVR. Survival times associated with the occurrence of HCC; survival of patients without HCC was excellent if they survived the first 6 months after initiation of antiviral therapy, whereas the survival rates of patients with HCC decreased persistently over time. A baseline MELD score above 20 and multiple complications were associated with short-term mortality. MVR was the factor most strongly associated with long-term transplant-free survival. Significantly higher proportions of patients who received entecavir survived 10 years compared with patients who received lamivudine, but no difference was observed among patients with MVRs. Patients with MVRs had significant improvement in hepatic function over time, but nonsignificant reductions in risk of HCC or HCC-related mortality. Conclusions: In a 10-year observation study of patients in Korea with HBV-related decompensated cirrhosis, we found baseline MELD score and MVR to entecavir or lamivudine to associate with short- and long-term transplant-free survival. The benefits of an MVR are maintained for up to 10 years even after decompensation, but patients are still at risk for HCC.

AB - Background & Aims: Little is known about the effects of antiviral therapy on short- and long-term survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis. We aimed to determine whether a maintained virologic response (MVR, defined as persistent undetectable HBV DNA during therapy) associates with short-term (6 mo) and long-term (6–120 mo) survival of patients with decompensated cirrhosis. Methods: We performed a 10-year observation analysis using data from the Epidemiology and Natural History of Liver Cirrhosis study of patients with decompensated liver cirrhosis in Korea. Of the entire cohort (1595 patients enrolled at onset of decompensation since 2005), our analysis comprised 295 patients who immediately began treatment with entecavir (n = 179) or lamivudine (n = 116) after decompensation. We collected laboratory test results, data on hepatocellular carcinoma (HCC) development, and Child–Turcotte–Pugh and model for end-stage liver disease (MELD) scores. The mean follow-up time was 62.3 ± 36.5 months. The primary end point was time of liver transplant-free survival. Results: The median survival time was 7.7 years; 60.1% of patients survived for 5 years and 45.7% survived for 10 years without liver transplantation. An MVR was observed in 116 patients (39.3%); these patients had significantly longer times of transplant-free survival than patients without MVR. Survival times associated with the occurrence of HCC; survival of patients without HCC was excellent if they survived the first 6 months after initiation of antiviral therapy, whereas the survival rates of patients with HCC decreased persistently over time. A baseline MELD score above 20 and multiple complications were associated with short-term mortality. MVR was the factor most strongly associated with long-term transplant-free survival. Significantly higher proportions of patients who received entecavir survived 10 years compared with patients who received lamivudine, but no difference was observed among patients with MVRs. Patients with MVRs had significant improvement in hepatic function over time, but nonsignificant reductions in risk of HCC or HCC-related mortality. Conclusions: In a 10-year observation study of patients in Korea with HBV-related decompensated cirrhosis, we found baseline MELD score and MVR to entecavir or lamivudine to associate with short- and long-term transplant-free survival. The benefits of an MVR are maintained for up to 10 years even after decompensation, but patients are still at risk for HCC.

UR - http://www.scopus.com/inward/record.url?scp=85054179796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054179796&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2018.04.063

DO - 10.1016/j.cgh.2018.04.063

M3 - Article

VL - 16

SP - 1954-1963.e3

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 12

ER -